The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors

International Journal of Biological Sciences

Volumn 2, Issue 4, 2006, Pages 179-185

  De Soto, Joseph A ^a   Wang, Xianyan ^a   Tominaga, Yohei ^a   Wang, Rui Hong ^a   Cao, Liu ^a   Qiao, Wenhui ^a   Li, Cuiling ^a   Xu, Xiaoling ^a   Skoumbourdis, Amanda P ^a   Prindiville, Sheila A ^b   Thomas, Craig J ^a   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRCA1; Breast cancer; PARP inhibitors; Tamoxifen; Therapeutic treatment

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ADENOSINE DIPHOSPHATE RIBOSE; AG 14361; BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST TUMOR; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; EMBRYONIC STEM CELL; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REGRESSION;

CRICETINAE;

EID: 33745867950     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.2.179     Document Type: Article

References (23)

1. Brody LC, and Biesecker BB. Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 1998; 77: 208-26.
2. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22.
3. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
4. Metcalfe KA. Prophylactic bilateral mastectomy for breast cancer prevention. J Womens Health (Larchmt) 2004; 13: 822-9.
5. Senkus-Konefka E, Konefka T, and Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004; 30: 291-301.
6. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
7. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
8. Hay T, Jenkins H, Sansom OJ, et al. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005; 65: 10145-8.
9. Brody LC. Treating cancer by targeting a weakness. N Engl J Med 2005; 353: 949-50.
10. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001; 20: 7514-23.
11. Papouli E, Lafon C, Valette A, et al. Involvement of apoptosis in mitomycin C hypersensitivity of Chinese hamster cell mutants. Biochem Pharmacol 2000; 59: 1101-7.
12. Zdzienicka MZ. Mammalian X ray sensitive mutants: a tool for the elucidation of the cellular response to ionizing radiation. Cancer Surv 1996; 28: 281-93.
13. Overkamp WJ, Rooimans MA, Neuteboom I, et al. Genetic diversity of mitomycin C-hypersensitive Chinese hamster cell mutants: a new complementation group with chromosomal instability. Somat Cell Mol Genet 1993; 19: 431-7.
14. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
15. Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998; 17: 3115-24.
16. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22: 37-43.
17. Elstrodt F, Hollestelle A, Nagel JH, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66: 41-5.
18. Weaver Z, Montagna C, Xu X, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002; 21: 5097-107.
19. Hanahan D, and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
20. Jones LP, Li M, Halama ED, et al. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 2005; 24: 3554-62.
21. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-81.
22. Gallmeier E, and Kern SE. Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-ribose) Polymerase Inhibition. Cancer Biol Ther 2005; 4: 703-6.
23. McCabe N, Lord CJ, Tutt AN, et al. BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency. Cancer Biol Ther 2005; 4: 934-6.